EUCTR2016-000708-26-IT进行中（未招募）1 期
Evaluation of clinical response in relation to the immunological status change in RRMS patients treated with Gilenya (fingolimod) for 12 months. - nd
FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE0 个研究点目标入组 50 人开始时间: 2021年6月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •They will be included in the study patients male or female aged> 18 years, affected from relapsing remitting multiple sclerosis with high disease activity. Patients will be eligible to treatment with fingolimod according to the data sheet of the drug. In summary, they are deemed eligible for treatment with fingolimod patients belonging to one of the following groups:
- •1) Patients with high disease activity despite treatment with a beta-interferon. These patients may be defined as those who have not responded to a full and adequate course of therapy (normally at least one year of treatment) of beta-interferon. Patients should have had at least 1 relapse in the previous year while on therapy, and have at least 9 T2-hyperintense lesions in cranial MRI or at least 1 Gadolinium-enhancing lesion. Patient non-responders can also be defined as a patient who has, over the previous year, an unchanged or increased relapse rate or who have severe relapses.
- •2) Patients with severe relapsing-remitting multiple sclerosis rapidly evolving, defined as two or more disabling relapses in one year, and with 1 or more gadolinium-enhancing lesions on brain MRI or a significant increase in T2 lesion load compared to a previous RM recently performed. For all therapeutic indications the dose is 0.5 mg orally, once daily.
- •3) The women of childbearing age will be enrolled only if they make use of highly effective contraceptive measures. The use of contraceptive measures must be extended to male patients with partners of childbearing age.
- •Highly effective contraceptive measures deemed, under specific CTFG the recommendations are as follows:
- •_ combined (estrogen and progestogen containing) hormonal contraception
- •associated with inhibition of ovulation 1:
- •o intravaginal
- •o transdermal
- •_ progestogen-only hormonal contraception associated with inhibition of ovulation 1:
- •o injectable
- •o implantable 2
- •_ intrauterine device (IUD)
- •_ intrauterine hormone-releasing system ( IUS)
- •_ bilateral tubal occlusion
- •_ vasectomised partner
- •_ sexual abstinence
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with HIV (a specific serologic testing for HIV should be conducted prior to initiating treatment with fingolimod).
- •Patients who are at increased risk for opportunistic infections, including immunocompromised patients (including those currently receiving immunosuppressive therapies or those immunocompromised by prior therapies).
- •Patients infected with HBV, HCV and HAV (before starting treatment with Gilenya should be performed the following serological tests: HBsAg, HBcAb, anti HCV antibodies, anti HAV IgM and IgG).
- •Patients with latent or active tuberculosis (before starting treatment with Gilenya should be performed dosing Quantiferon test)
- •Malignant tumors diagnosed in the active phase.
- •Severe hepatic impairment (Child-Pugh Class C).
- •Hypersensitivity to the active substance or to any of the excipients.
- •Patients treated with live vaccines within 30 days prior to screening
- •Women of childbearing potential and not complianti highly effective contraceptive measures defined in accordance with the recommendations of the Clinical Trial Facilitation Group (http://www.hma.eu/fileadmin/dateien/Human_Medicines/01About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf)
- •Male patients with partners of childbearing age who do not belong to highly effective contraceptive measures defined in accordance with the recommendations of Clinical Trial Facilitation Group
- •Women who are pregnant or breast-feeding (in all women of childbearing age before you start treatment with Gilenya will be made the dosage of beta-HCG in serum, and also will be made a urinary pregnancy test every month during treatment as required by the recommendations of the Clinical Trial Facilitation Group)
- •Patients with moderate to severe heart failure (III / IV class according to the New York Heart Association)
- •Documented relapse or steroid therapy ev a month before the start of therapy
- •Patients who have discontinued treatment with fingolimod following an inadequate response
研究者
相似试验
已完成
不适用
Study on clinical characteristics and response of growth hormone(GH) during GH releasing peptide (GHRP)-2 test in patients with non-functioning pituitary adenomasJPRN-UMIN000035557ippon Medical School Hospital76
尚未招募
不适用
The Effect of Yashtyadi Kwath and Shunthyadi Pindi in the Management of Praklinna Vartma with special reference to Squamous BlepharitisCTRI/2022/07/044243Dr Akash Pralhad Gaikwad
招募中
不适用
Clinical observational study for evaluation of the therapy outcome and the dependency of the outcome on parameters as reconstruction type and/or vitamin D level in OMS tumor patients in need of intra-oral tumor resection and reconstructioC01C02C03C04C05C06C44C40C41C07C08C09C10C11C12C13C14Malignant neoplasm of base of tongueMalignant neoplasm of other and unspecified parts of tongueMalignant neoplasm of gumMalignant neoplasm of floor of mouthMalignant neoplasm of palateMalignant neoplasm of other and unspecified parts of mouthOther malignant neoplasms of skinMalignant neoplasm of bone and articular cartilage of limbsMalignant neoplasm of bone and articular cartilage of other and unspecified sitesMalignant neoplasm of parotid glandMalignant neoplasm of other and unspecified major salivary glandsMalignant neoplasm of tonsilMalignant neoplasm of oropharynxMalignant neoplasm of nasopharynxMalignant neoplasm of piriform sinusMalignant neoplasm of hypopharynxMalignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynxDRKS00025841niversitätsklinikum derGoethe-Universität Frankfurt am MainKlinik für Mund-, Kiefer- und Plastische Gesichtschirurgie100
尚未招募
3 期
A comparative clinical study to assess the role of raktamokshana (modified shringa yantra) with panchatikta ghrita guggulu and agnikarma with panchatikta ghrita guggulu in the management of manyagata vata w.s.r. to cervical spondylosis.CTRI/2024/07/071570Dr Kirti chahal
已完成
2 期
To compare the effect of ayurvedic digestive medicines before controlled purgetive procedure in treatment of acne.CTRI/2023/01/048790ational Institute Of Ayurveda30